- Home
- MPAA vs ANVS Comparison
MPAA vs ANVS Comparison
Compare MPAA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPAA | ANVS |
|---|---|---|
| Founded | 1968 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.3M | 69.1M |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MPAA | ANVS |
|---|---|---|
| Price | $11.37 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.50 | $13.50 |
| AVG Volume (30 Days) | 43.6K | ★ 954.1K |
| Earning Date | 06-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.56 | 39.39 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $757,354,000.00 | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $86.00 | ★ N/A |
| Revenue Growth | ★ 5.53 | N/A |
| 52 Week Low | $9.29 | $1.54 |
| 52 Week High | $18.12 | $5.50 |
Technical Indicators
Market Signals| Indicator | MPAA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 50.12 |
| Support Level | $9.83 | $1.86 |
| Resistance Level | $12.13 | $2.29 |
| Average True Range (ATR) | 0.50 | 0.17 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 40.65 | 54.13 |
Price Performance
Historical ComparisonAbout MPAA Motorcar Parts of America Inc.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.